Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, announced that it has secured $17 million in a subsequent financing round. Terms of the investment were not disclosed.
The company noted that Domain Associates, LLC led the financing round, and AgeChem Venture Fund LP joined previous investors Thomas, McNerney & Partners, LLC, Forward Ventures and Isis Pharmaceuticals, Inc. (ISIS)
San Diego-based Altair said it has planned to utilize the funding to complete phase 2a trials for its inhaled AIR645 product and advance research and development in new target programs.
Joel Martin, President and CEO of Altair Therapeutics, said, "We are thrilled to have Domain Associates and Agechem Venture Fund join our investor syndicate,"
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.